Literature DB >> 32479105

Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer.

Jeries P Zawaideh1, Evis Sala1,2, Maria Pantelidou1, Nadeem Shaida1,2, Brendan Koo1, Iztok Caglic1, Anne Y Warren2,3, Luca Carmisciano4, Kasra Saeb-Parsy2,5, Vincent J Gnanapragasam2,5, Christof Kastner2,5, Tristan Barrett1,2.   

Abstract

OBJECTIVE: To compare the performance of Likert and Prostate Imaging-Reporting and Data System (PI-RADS) multiparametric (mp) MRI scoring systems for detecting clinically significant prostate cancer (csPCa).
METHODS: 199 biopsy-naïve males undergoing prostate mpMRI were prospectively scored with Likert and PI-RADS systems by four experienced radiologists. A binary cut-off (threshold score ≥3) was used to analyze histological results by three groups: negative, insignificant disease (Gleason 3 + 3; iPCa), and csPCa (Gleason ≥3 +4). Lesion-level results and prostate zonal location were also compared.
RESULTS: 129/199 (64.8%) males underwent biopsy, 96 with Likert or PI-RADS score ≥3, and 21 with negative MRI. A further 12 patients were biopsied during follow-up (mean 507 days). Prostate cancer was diagnosed in 87/199 (43.7%) patients, 65 with (33.6%) csPCa. 30/92 (32.6%) patients with negative MRI were biopsied, with an NPV of 83.3% for cancer and 86.7% for csPCa. Likert and PI-RADS score differences were observed in 92 patients (46.2%), but only for 16 patients (8%) at threshold score ≥3. Likert scoring had higher specificity than PI-RADS (0.77 vs 0.66), higher area under the curve (0.92 vs 0.87, p = 0.002) and higher PPV (0.66 vs 0.58); NPV and sensitivity were the same. Likert had more five score results (58%) compared to PI-RADS (36%), but with similar csCPa detection (81.0 and 80.6% respectively). Likert demonstrated lower proportion of false positive in the predominately AFMS-involving lesions.
CONCLUSION: Likert and PI-RADS systems both demonstrate high cancer detection rates. Likert scoring had a higher AUC with moderately higher specificity and lower positive call rate and could potentially help to reduce the number of unnecessary biopsies performed. ADVANCES IN KNOWLEDGE: This paper illustrates that the Likert scoring system has potential to help urologists reduce the number of prostate biopsies performed.

Entities:  

Mesh:

Year:  2020        PMID: 32479105      PMCID: PMC7446003          DOI: 10.1259/bjr.20200298

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  22 in total

1.  Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI.

Authors:  Andrew B Rosenkrantz; Ruth P Lim; Mershad Haghighi; Molly B Somberg; James S Babb; Samir S Taneja
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

2.  Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.

Authors:  Raphaëlle Renard-Penna; Pierre Mozer; François Cornud; Nicolas Barry-Delongchamps; Eric Bruguière; Daniel Portalez; Bernard Malavaud
Journal:  Radiology       Date:  2015-01-19       Impact factor: 11.105

3.  The Learning Curve in Prostate MRI Interpretation: Self-Directed Learning Versus Continual Reader Feedback.

Authors:  Andrew B Rosenkrantz; Abimbola Ayoola; David Hoffman; Anunita Khasgiwala; Vinay Prabhu; Paul Smereka; Molly Somberg; Samir S Taneja
Journal:  AJR Am J Roentgenol       Date:  2016-12-27       Impact factor: 3.959

4.  Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold?

Authors:  Julie Y An; Stephanie A Harmon; Sherif Mehralivand; Marcin Czarniecki; Clayton P Smith; Julie A Peretti; Bradford J Wood; Peter A Pinto; Peter L Choyke; Joanna H Shih; Baris Turkbey
Journal:  Abdom Radiol (NY)       Date:  2018-12

Review 5.  PI-RADS version 2: what you need to know.

Authors:  T Barrett; B Turkbey; P L Choyke
Journal:  Clin Radiol       Date:  2015-07-29       Impact factor: 2.350

6.  Sub-differentiating equivocal PI-RADS-3 lesions in multiparametric magnetic resonance imaging of the prostate to improve cancer detection.

Authors:  N L Hansen; B C Koo; A Y Warren; C Kastner; T Barrett
Journal:  Eur J Radiol       Date:  2017-08-24       Impact factor: 3.528

Review 7.  Similarities and differences between Likert and PIRADS v2.1 scores of prostate multiparametric MRI: a pictorial review of histology-validated cases.

Authors:  A Latifoltojar; M B Appayya; T Barrett; S Punwani
Journal:  Clin Radiol       Date:  2019-11       Impact factor: 2.350

8.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

9.  Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer.

Authors:  Christopher C Khoo; David Eldred-Evans; Max Peters; Mariana Bertoncelli Tanaka; Mohamed Noureldin; Saiful Miah; Taimur Shah; Martin J Connor; Deepika Reddy; Martin Clark; Amish Lakhani; Andrea Rockall; Feargus Hosking-Jervis; Emma Cullen; Manit Arya; David Hrouda; Hasan Qazi; Mathias Winkler; Henry Tam; Hashim U Ahmed
Journal:  BJU Int       Date:  2019-11-01       Impact factor: 5.969

10.  Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool.

Authors:  Gabriele Gaziev; Karan Wadhwa; Tristan Barrett; Brendan C Koo; Ferdia A Gallagher; Eva Serrao; Julia Frey; Jonas Seidenader; Lina Carmona; Anne Warren; Vincent Gnanapragasam; Andrew Doble; Christof Kastner
Journal:  BJU Int       Date:  2015-05-11       Impact factor: 5.588

View more
  5 in total

Review 1.  Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway.

Authors:  Tristan Barrett; Maarten de Rooij; Francesco Giganti; Clare Allen; Jelle O Barentsz; Anwar R Padhani
Journal:  Nat Rev Urol       Date:  2022-09-27       Impact factor: 16.430

2.  Impact of MRI/US fusion-guided prostate biopsy on biopsy-naïve patients: A single urologist's experience.

Authors:  Muammer Altok; Cihan Demirel; Hyunseon C Kang; Haesun Choi; David John; Irene A Inguillo; John W Davis; John F Ward
Journal:  BJUI Compass       Date:  2021-05-04

3.  Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial.

Authors:  Hayley Pye; Saurabh Singh; Joseph M Norris; Lina M Carmona Echeverria; Vasilis Stavrinides; Alistair Grey; Eoin Dinneen; Elly Pilavachi; Joey Clemente; Susan Heavey; Urszula Stopka-Farooqui; Benjamin S Simpson; Elisenda Bonet-Carne; Dominic Patel; Peter Barker; Keith Burling; Nicola Stevens; Tony Ng; Eleftheria Panagiotaki; David Hawkes; Daniel C Alexander; Manuel Rodriguez-Justo; Aiman Haider; Alex Freeman; Alex Kirkham; David Atkinson; Clare Allen; Greg Shaw; Teresita Beeston; Mrishta Brizmohun Appayya; Arash Latifoltojar; Edward W Johnston; Mark Emberton; Caroline M Moore; Hashim U Ahmed; Shonit Punwani; Hayley C Whitaker
Journal:  Cancers (Basel)       Date:  2021-04-20       Impact factor: 6.575

4.  Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population.

Authors:  Artitaya Lophatananon; Matthew H V Byrne; Tristan Barrett; Anne Warren; Kenneth Muir; Ibifuro Dokubo; Fanos Georgiades; Mostafa Sheba; Lisa Bibby; Vincent J Gnanapragasam
Journal:  BMC Cancer       Date:  2022-08-11       Impact factor: 4.638

5.  Comparison of the effect of melatonin, dexmedetomidine, and gabapentin on reduction of postoperative pain and anxiety following laminectomy: a randomized clinical trial.

Authors:  Reza Jouybar; Somayeh Kazemifar; Naeimehossadat Asmarian; Ali Karami; Saeed Khademi
Journal:  BMC Anesthesiol       Date:  2022-10-15       Impact factor: 2.376

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.